ADVAXIS, INC. DEBT CONVERSION AND REPAYMENT AGREEMENTDebt Conversion and Repayment Agreement • September 27th, 2013 • Advaxis, Inc. • Pharmaceutical preparations • Delaware
This Debt Conversion and Repayment Agreement (this “Agreement”) is made this 26th day of September, 2013 (the “Effective Date”), by and between Advaxis, Inc., a Delaware corporation (the “Company”) and Thomas A. Moore (“Holder”), a Director of the Company. The Company and Holder are sometimes referred to herein collectively as the “Parties.”
EXCHANGE AGREEMENTExchange Agreement • September 27th, 2013 • Advaxis, Inc. • Pharmaceutical preparations • New York
EXCHANGE AGREEMENT (the “Agreement”) is made as of the 27th day of September 2013 (the “Effective Date”), by and between Advaxis, Inc., a Delaware corporation (the “Company”), and Redwood Management, LLC (the “Investor”).
NOTICE OF REDEMPTION AND SETTLEMENT AGREEMENTNotice of Redemption and Settlement Agreement • September 27th, 2013 • Advaxis, Inc. • Pharmaceutical preparations • New York
NOTICE OF REDEMPTION AND SETTLEMENT AGREEMENT (the “Agreement”) is made as of the 26th day of September 2013 by and among Advaxis, Inc., a Delaware corporation (the “Company”), Optimus Capital Partners, LLC, a Delaware limited liability company, dba Optimus Life Sciences Capital Partners, LLC (“Optimus Life Sciences”), Optimus CG II, Ltd., a Cayman Islands exempted Company (“Optimus CG II”), Socius CG II, Ltd., a Bermuda exempted Company (“Socius” and collectively with Optimus Life Sciences, Optimus CG II and their respective designees, the “Investors”), and, solely for purposes of Section 2.4, Crede CG III, Ltd., a wholly owned-subsidiary of Crede Capital Group, LLC. (“Crede”).
